How to buy Cellectar Biosciences stock (CLRB)

Cellectar Biosciences is a biotechnology business based in the US. Cellectar Biosciences shares (CLRB) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.25 – a decrease of 5.68% over the previous week. Cellectar Biosciences employs 20 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Cellectar Biosciences stock

Buy Cellectar Biosciences stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Cellectar Biosciences stock price (NASDAQ: CLRB)

Use our graph to track the performance of CLRB stocks over time.

Cellectar Biosciences shares at a glance

• Key figures

Information last updated 2024-12-11.

Latest market close	$0.25
52-week range	$0.27 - $4.45
50-day moving average more info button	$1.90
200-day moving average more info button	$2.63
Wall St. target price	$7.67
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.41

Is it a good time to buy Cellectar Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cellectar Biosciences price performance over time

Historical closes compared with the close of $0.2624 from 2024-12-17

1 week (2024-12-12)	-0.61%
1 month (2024-11-19)	-83.70%
3 months (2024-09-19)	-87.56%
6 months (2024-06-18)	-90.17%

1 year (2023-12-19)	-89.91%
2 years (2022-12-19)	-79.34%
3 years (2021-12-17)	6.9
5 years (2019-12-19)	21.5

Cellectar Biosciences financials

Gross profit TTM	$0
Return on assets TTM	-166%
Return on equity TTM	-796.67%
Profit margin	0%
Book value	$-0.96
Market Capitalization more info button	$12.6 million

TTM: trailing 12 months

Cellectar Biosciences share dividends

We're not expecting Cellectar Biosciences to pay a dividend over the next 12 months.

Have Cellectar Biosciences's shares ever split?

Cellectar Biosciences's shares were split on a 1:10 basis on 21 July 2022 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cellectar Biosciences shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Cellectar Biosciences shares which in turn could have impacted Cellectar Biosciences's share price.

Cellectar Biosciences share price volatility

Over the last 12 months, Cellectar Biosciences's shares have ranged in value from as little as $0.2747 up to $4.45. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cellectar Biosciences's is 1.007. This would suggest that Cellectar Biosciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Cellectar Biosciences overview

Cellectar Biosciences, Inc. , a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey. .

Frequently asked questions

null
What percentage of Cellectar Biosciences is owned by insiders or institutions?
Currently 2.839% of Cellectar Biosciences shares are held by insiders and 34.549% by institutions. How many people work for Cellectar Biosciences?
Latest data suggests 20 work at Cellectar Biosciences. When does the fiscal year end for Cellectar Biosciences?
Cellectar Biosciences's fiscal year ends in December. Where is Cellectar Biosciences based?
Cellectar Biosciences's address is: 100 Campus Drive, Florham Park, NJ, United States, 07932 What is Cellectar Biosciences's ISIN number?
Cellectar Biosciences's international securities identification number is: US15117F5008 What is Cellectar Biosciences's CUSIP number?
Cellectar Biosciences's Committee on Uniform Securities Identification Procedures number is: 67000M100